Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming CEO in 2018.

Antibody-based cancer therapy company Genmab A/S (CSE:GMAB; NASDAQ:GMAB) hired Anthony Mancini as EVP and COO, effective March 23. He was SVP and head of the U.S. innovative medicines unit of Bristol Myers Squibb Co. (NYSE:BMY)...